8 August 2014

ASX ANNOUNCEMENT

ImpediMed (ASX:IPD)

ImpediMed CEO discusses reimbursement strategy in BRR audio broadcast

ImpediMed (ASX:IPD) has today released an audio recording of an investor presentation about the company’s reimbursement strategy.

In the presentation titled “Getting to CPT1”, CEO Richard Carreon discusses how the company achieved Category 1 CPT reimbursement code, which is the highest government pay code available in the US, for its L-Dex device used for the early detection of Lymphoedema.

This presentation was first delivered at the Bioshares Biotech Summit in July 2014.

To listen and view the slides, copy the following details into your web browser:

http://www.brrmedia.com/event/preview/zFeh6e7p/124931?popup=true

ENDS

For further information contact:
Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au